Apple Vision Pro can now be controlled using the Brain-Computer Interface

Apple’s Vision Pro headset can now be controlled with just thoughts, thanks to an integration with neurotechnology startup Synchron’s brain-computer interface (BCI).

The company announced today that Apple Vision Pro has been successfully used by a patient through direct brain control using Synchron’s brain-computer interface technology. Mark, a 64-year-old man suffering from amyotrophic lateral sclerosis (ALS), demonstrated integration.

With this technology, Mark controlled the cursor on the Vision Pro to play Solitaire, watch Apple TV and send text messages without using his hands, which he can no longer use due to his condition. The Vision Pro’s reliance on hand gestures would otherwise be a barrier for users like Mark who have lost upper limb functionality.

Mark has practiced various skills and functions with his BCI twice a week since its implantation in August 2023. He noted that using the BCI to control the Vision Pro is similar to using it for his iPhone, iPad and computer. Apple’s suite of accessibility features across its platforms has been praised for its excellence, which is why Synchron initially focused on BCI integration with Apple devices.

Synchron’s brain-computer interface allows individuals with severe physical limitations to control digital devices with their thoughts. The BCI is implanted into a blood vessel on the surface of the motor cortex through a minimally invasive endovascular procedure. The device detects motor intent from the brain and wirelessly transmits these signals to external devices, enabling hands-free control. Tom Oxley, CEO and founder of Synchron, said:

BCI is a platform for reconnecting people with injury or illness back into the rapidly evolving consumer technology landscape. Vision Pro is a powerful system, but it relies on using hand gestures to control the user interface. We send control signals directly from the brain to replace the need for hand gestures. We’re moving toward a new Bluetooth standard for human-computer interactions that doesn’t require touch or speech. This is a critical unmet need for millions of people with paralysis.

Synchron is preparing for larger clinical trials to expand the reach of its BCI technology. It has implanted its BCI in six patients in the United States and four in Australia. The company continues to apply to the US Food and Drug Administration to commercialize its technology.